The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Frank M. Sacks

Harvard School of Public Health

Department of Nutrition

665 Huntington Ave

Bldg 1

[email]@*.harvard.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Harvard School of Public Health, Department of Nutrition, 665 Huntington Ave, Bldg 1. 2011
  • Harvard School of Public Health and Harvard Medical School, Boston, USA. 2009
  • Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. 1998 - 2008
  • Cardiovascular Disease Prevention, Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, USA. 2008
  • Brigham and Women's Hospital, Harvard Medical School Boston, MA 02115, USA. 2000
  • Department of Medicine, Harvard Medical School, USA. 1999

References

  1. Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease. Mendivil, C.O., Rimm, E.B., Furtado, J., Chiuve, S.E., Sacks, F.M. Circulation (2011) [Pubmed]
  2. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. Sacks, F.M., Rudel, L.L., Conner, A., Akeefe, H., Kostner, G., Baki, T., Rothblat, G., de la Llera-Moya, M., Asztalos, B., Perlman, T., Zheng, C., Alaupovic, P., Maltais, J.A., Brewer, H.B. J. Lipid Res. (2009) [Pubmed]
  3. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction. Sacks, F.M. Am. J. Cardiol. (2008) [Pubmed]
  4. Major potential of diet treatment for type 2 diabetes. Sacks, F.M. Curr. Diab. Rep. (2008) [Pubmed]
  5. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Sacks, F.M. Am. J. Cardiol. (2008) [Pubmed]
  6. The apolipoprotein story. Sacks, F.M. Atheroscler. Suppl (2006) [Pubmed]
  7. Metabolic syndrome: epidemiology and consequences. Sacks, F.M. J. Clin. Psychiatry (2004) [Pubmed]
  8. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. Sacks, F.M., Campos, H. J. Clin. Endocrinol. Metab. (2003) [Pubmed]
  9. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Sacks, F.M., Tonkin, A.M., Craven, T., Pfeffer, M.A., Shepherd, J., Keech, A., Furberg, C.D., Braunwald, E. Circulation (2002) [Pubmed]
  10. Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins. Sacks, F.M., Alaupovic, P., Moye, L.A. Am. J. Cardiol. (2002) [Pubmed]
  11. Dietary fat, the Mediterranean diet, and health: reports from scientific exchanges, 1998 and 2000. Introduction. Sacks, F.M. Am. J. Med. (2002) [Pubmed]
  12. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Sacks, F.M., Katan, M. Am. J. Med. (2002) [Pubmed]
  13. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. Sacks, F.M., Svetkey, L.P., Vollmer, W.M., Appel, L.J., Bray, G.A., Harsha, D., Obarzanek, E., Conlin, P.R., Miller, E.R., Simons-Morton, D.G., Karanja, N., Lin, P.H. N. Engl. J. Med. (2001) [Pubmed]
  14. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Sacks, F.M. Am. J. Cardiol. (2001) [Pubmed]
  15. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Sacks, F.M., Alaupovic, P., Moye, L.A., Cole, T.G., Sussex, B., Stampfer, M.J., Pfeffer, M.A., Braunwald, E. Circulation (2000) [Pubmed]
  16. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Sacks, F.M., Tonkin, A.M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C.M., Keech, A., Packard, C., Simes, J., Byington, R., Furberg, C.D. Circulation (2000) [Pubmed]
  17. Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Sacks, F.M., Ridker, P.M. Herz (1999) [Pubmed]
  18. Effect on blood pressure of potassium, calcium, and magnesium in women with low habitual intake. Sacks, F.M., Willett, W.C., Smith, A., Brown, L.E., Rosner, B., Moore, T.J. Hypertension (1998) [Pubmed]
  19. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Sacks, F.M., Moyé, L.A., Davis, B.R., Cole, T.G., Rouleau, J.L., Nash, D.T., Pfeffer, M.A., Braunwald, E. Circulation (1998) [Pubmed]
 
WikiGenes - Universities